Chen Qi, Chen Jie, Liu Yi-Ning, Qi Su-Hua, Huang Lin-Yan
Xuzhou Key Laboratory of Laboratory Diagnostics, School of Medical Technology, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China.
Authors contributed equally.
Extracell Vesicles Circ Nucl Acids. 2023 Sep 4;4(3):502-517. doi: 10.20517/evcna.2023.32. eCollection 2023.
Diabetes medication is based on controlling blood glucose and delaying the onset of related complications and is not a complete cure for diabetes. Conventional drug therapy fails to stop progressive islet β cell failure in diabetic patients. Recent studies have shown that "exosome-based therapy" holds great promise in treating diabetes and its complications. Exosomes are small vesicles that are stable in the bloodstream and can effectively deliver therapeutic drugs to specific tissues or organs through intercellular communication. Using exosomes as carriers for drug delivery offers several advantages. This review summarizes the benefits of exosomal drug delivery systems, drug loading methods, and their applications in treating diabetes and its complications. However, there are still challenges to overcome in using exosomal drug delivery systems, such as large-scale production, assessing the contents of exosomes, and monitoring the safety and effectiveness of the treatment . In conclusion, this review proposes the therapeutical potential of exosomes as drug carriers for developing novel drugs to provide new strategies for treating diabetes and its complications.
糖尿病药物治疗基于控制血糖水平和延缓相关并发症的发生,而非完全治愈糖尿病。传统药物疗法无法阻止糖尿病患者胰岛β细胞的渐进性衰竭。最近的研究表明,“基于外泌体的疗法”在治疗糖尿病及其并发症方面具有巨大潜力。外泌体是在血液中稳定存在的小囊泡,能够通过细胞间通讯有效地将治疗药物递送至特定组织或器官。以外泌体作为药物递送载体具有诸多优势。本综述总结了外泌体药物递送系统的优势、药物装载方法及其在治疗糖尿病及其并发症中的应用。然而,在外泌体药物递送系统的应用中仍存在一些挑战需要克服,例如大规模生产、评估外泌体的内容物以及监测治疗的安全性和有效性。总之,本综述提出了外泌体作为药物载体在开发新型药物方面的治疗潜力,为治疗糖尿病及其并发症提供了新策略。